Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Up 709.3% in December

Evaxion Biotech A/S (NASDAQ:EVAX) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 980,100 shares, a growth of 709.3% from the December 15th total of 121,100 shares. Based on an average daily trading volume, of 335,500 shares, the days-to-cover ratio is presently 2.9 days.

Evaxion Biotech A/S Stock Performance

Shares of NASDAQ:EVAX traded down $0.47 during trading on Tuesday, reaching $3.78. 135,045 shares of the company’s stock traded hands, compared to its average volume of 53,329. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. Evaxion Biotech A/S has a 12 month low of $3.32 and a 12 month high of $68.05. The company has a 50 day moving average of $6.75 and a 200-day moving average of $11.93. The stock has a market capitalization of $22.17 million, a P/E ratio of -13.03 and a beta of -0.23.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its earnings results on Thursday, October 31st. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.40. The firm had revenue of $3.02 million during the quarter, compared to the consensus estimate of $0.19 million. On average, equities analysts expect that Evaxion Biotech A/S will post -0.15 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Invst LLC acquired a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned approximately 1.00% of Evaxion Biotech A/S at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of Evaxion Biotech A/S in a research note on Friday, November 1st.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.